Kite’s CAR-T Therapy Makes It Back Onto EMA’s PRIME, Along With Three New Products

The four latest products to be accepted onto the European Medicines Agency’s popular priority medicines scheme target mantle cell lymphoma, chikungunya, hematopoietic stem cell transplant patients, and the rare monogenic disease, X-linked myotubular myopathy.

3d illustration of T cells or cancer cells
Kite's CAR-T therapy is among the four new products accepted onto the PRIME scheme

Four new products have made it onto the European Medicines Agency’s priority medicines (PRIME) scheme, including Kite Pharma’s chimeric antigen receptor T cell (CAR T) therapy, axicabtagene ciloleucel, which has been accepted onto the popular scheme for the second time, for a new indication.

Axicabtagene ciloleucel (KTE-C19) was originally accepted for the treatment of refractory diffuse large B-cell lymphoma (DLBCL). It has now been...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet